Inavir is the first of a new class of long acting neuraminidase inhibitors (LANIs) designed to address the limitation of the current influenza anti-virals, which require daily or more frequent dosing
The Phase III double-blind, multicenter, placebo-controlled trial investigated the prevention and safety of laninamivir octanoate in families of influenza A and B sufferers.
The trial results showed the protective efficacies of a single, inhaled dose of CS-8958 of 20mg and 40mg were 43.7% and 43.2% respectively but were lower than the preset RRR endpoint of 70% as as measured by the Risk Reduction Rate (RRR).